<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Euda Health Holdings Limited — News on 6ix</title>
<link>https://6ix.com/company/euda-health-holdings-limited</link>
<description>Latest news and press releases for Euda Health Holdings Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/euda-health-holdings-limited" rel="self" type="application/rss+xml" />
<item>
<title>EUDA Announces Reverse Stock Split of its Ordinary Shares</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-announces-reverse-stock-split-of-its-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-announces-reverse-stock-split-of-its-ordinary-shares</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>SINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare</description>
</item>
<item>
<title>EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-health-holdings-limited-announces-repurchase-and-cancellation-of-streeterville-warrant</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-health-holdings-limited-announces-repurchase-and-cancellation-of-streeterville-warrant</guid>
<pubDate>Wed, 04 Mar 2026 14:10:00 GMT</pubDate>
<description>SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC. Background of the Warrant As previously disclosed, the Company entered into a securities purchase agreement dated November 26, 2025 with an accredited investor</description>
</item>
<item>
<title>EUDA Health Announces Second Amendment to Streeterville Warrant Agreement</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-health-announces-second-amendment-135900840</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-health-announces-second-amendment-135900840</guid>
<pubDate>Thu, 15 Jan 2026 13:59:00 GMT</pubDate>
<description>SINGAPORE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has entered into a second amendment to its previously disclosed warrant agreement with Streeterville Capital, LLC. Summary of Second Warrant Amendment Terms Under the terms of the Second Warrant Amendment dated January 13, 2026, the Company and Streeterville</description>
</item>
<item>
<title>EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-enters-convertible-loan-agreement-124900134</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-enters-convertible-loan-agreement-124900134</guid>
<pubDate>Tue, 13 Jan 2026 12:49:00 GMT</pubDate>
<description>SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutics and customised medicines for a wide range of</description>
</item>
<item>
<title>EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-health-holdings-limited-announces-110000504</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-health-holdings-limited-announces-110000504</guid>
<pubDate>Wed, 07 Jan 2026 11:00:00 GMT</pubDate>
<description>SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered into an amendment (the “Warrant Amendment”) to its previously disclosed warrant agreement with Streeterville Capital, LLC (“Streeterville Capital”). Background on the Original Warrant Transaction As previously announced, on November 26, 2025, EUDA</description>
</item>
<item>
<title>EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-launches-nationwide-stem-cell-120000730</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-launches-nationwide-stem-cell-120000730</guid>
<pubDate>Tue, 30 Dec 2025 12:00:00 GMT</pubDate>
<description>SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company,” a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital as the Company continues to expand its national clinical and logistics</description>
</item>
<item>
<title>EUDA Health to Launch EUDA Helixé 2.0 in January 2026</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-health-launch-euda-helix-120000974</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-health-launch-euda-helix-120000974</guid>
<pubDate>Mon, 29 Dec 2025 12:00:00 GMT</pubDate>
<description>SINGAPORE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it will launch EUDA Helixé 2.0 in January 2026, marking the next generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixé 2.0 introduces enhancements across formulation strength, ingredient technology, delivery systems, packaging</description>
</item>
<item>
<title>EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-accelerates-longevity-strategy-launch-120000896</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-accelerates-longevity-strategy-launch-120000896</guid>
<pubDate>Tue, 23 Dec 2025 12:00:00 GMT</pubDate>
<description>SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and establishment of its first clinic in Shenzhen, China. This strategic advancement builds on the Company’s earlier acquisitio</description>
</item>
<item>
<title>EUDA Integrates QB Utility Token to Create a Digital Health and Rewards Platform Across Its Healthcare Ecosystem</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-integrates-qb-utility-token-to-create-a-digital-health-and-rewards-platform-across-its-healthcare-ecosystem</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-integrates-qb-utility-token-to-create-a-digital-health-and-rewards-platform-across-its-healthcare-ecosystem</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>SINGAPORE, Dec. 22, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare</description>
</item>
<item>
<title>EUDA Plans to Integrate QB Utility Token into Its Healthcare Ecosystem</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-plans-to-integrate-qb-utility-token-into-its-healthcare-ecosystem</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-plans-to-integrate-qb-utility-token-into-its-healthcare-ecosystem</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based leading non-invasive</description>
</item>
<item>
<title>EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-health-holdings-limited-announces-143000813</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-health-holdings-limited-announces-143000813</guid>
<pubDate>Fri, 05 Dec 2025 14:30:00 GMT</pubDate>
<description>SINGAPORE, Dec. 05, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or “the Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it entered into a securities purchase agreement on November 26, 2025 with Streeterville Capital, LLC, a Utah limited liability company, for the sale of a convertible warrant (the “Warrant”) for an aggregate purchase price of US$100,000. The Warrant is exercisab</description>
</item>
<item>
<title>EUDA Subsidiary CK Health Plus Expands into India in Strategic Partnership with SafeRock India</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-subsidiary-ck-health-plus-130000189</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-subsidiary-ck-health-plus-130000189</guid>
<pubDate>Thu, 23 Oct 2025 13:00:00 GMT</pubDate>
<description>SINGAPORE, Oct. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. (“CK Health Plus”), will expand into the Indian market through a strategic master license and representative partnership with SafeRock India Private Limited (“SafeRock India”), a SafeRock India Private Limit</description>
</item>
<item>
<title>EUDA Subsidiary CK Health Plus Secures Malaysia Direct Selling License, Strengthening Its Longevity Business Across Asia</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-subsidiary-ck-health-plus-130000872</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-subsidiary-ck-health-plus-130000872</guid>
<pubDate>Mon, 20 Oct 2025 13:00:00 GMT</pubDate>
<description>SINGAPORE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. (“CK Health Plus”), has been granted a Direct Selling License (AJL 932509) (the “License”) by the Malaysian Ministry of Domestic Trade and Cost of Living. License Approval and Compliance The License marks a</description>
</item>
<item>
<title>EUDA Signs Letter of Intent to Potentially Acquire GO POSB</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-signs-letter-intent-potentially-133000635</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-signs-letter-intent-potentially-133000635</guid>
<pubDate>Wed, 10 Sep 2025 13:30:00 GMT</pubDate>
<description>SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has signed a Letter of Intent (the “LOI”) to potentially acquire GO POSB Organoids Pte Ltd (“GO POSB”), a biotechnology company formed in Singapore. GO POSB has developed a proprietary induced</description>
</item>
<item>
<title>EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-strategically-expands-t-cell-120000150</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-strategically-expands-t-cell-120000150</guid>
<pubDate>Thu, 04 Sep 2025 12:00:00 GMT</pubDate>
<description>SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China.</description>
</item>
<item>
<title>EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-signs-letter-intent-potentially-120000232</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-signs-letter-intent-potentially-120000232</guid>
<pubDate>Thu, 28 Aug 2025 12:00:00 GMT</pubDate>
<description>SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chemokine Pte Ltd (“Chemokine”). EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hu</description>
</item>
<item>
<title>EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-expands-wellness-product-portfolio-120000331</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-expands-wellness-product-portfolio-120000331</guid>
<pubDate>Tue, 26 Aug 2025 12:00:00 GMT</pubDate>
<description>SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the “Supplement”) from Chemokine Pte. Ltd. (“Chemokine”), a Singapore-based biotech company focused o</description>
</item>
<item>
<title>EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-partners-authorized-distributor-guangdong-110000740</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-partners-authorized-distributor-guangdong-110000740</guid>
<pubDate>Thu, 24 Apr 2025 11:00:00 GMT</pubDate>
<description>SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”). Guangdong Cell Biotech is a prominent player in stem cell therapies and regenerativ</description>
</item>
<item>
<title>EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-holdings-and-guangdong-cell-biotech-explore-potential-strategic-partnership-to-advance-biotechnology-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-holdings-and-guangdong-cell-biotech-explore-potential-strategic-partnership-to-advance-biotechnology-innovation</guid>
<pubDate>Mon, 16 Dec 2024 05:00:00 GMT</pubDate>
<description>- Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the</description>
</item>
<item>
<title>EUDA Health Holdings Limited Completes Acquisition of CK Health Plus Sdn Bhd, Expanding into Direct Selling Holistic Wellness Products in Southeast Asia</title>
<link>https://6ix.com/company/euda-health-holdings-limited/news/euda-health-holdings-limited-completes-acquisition-of-ck-health-plus-sdn-bhd-expanding-into-direct-selling-holistic-wellness-products-in-southeast-asia</link>
<guid isPermaLink="true">https://6ix.com/company/euda-health-holdings-limited/news/euda-health-holdings-limited-completes-acquisition-of-ck-health-plus-sdn-bhd-expanding-into-direct-selling-holistic-wellness-products-in-southeast-asia</guid>
<pubDate>Wed, 08 May 2024 04:00:00 GMT</pubDate>
<description>Singapore, May 08, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company</description>
</item>
</channel>
</rss>